NasdaqCM - Nasdaq Real Time Price USD

Spruce Biosciences, Inc. (SPRB)

Compare

0.2910

-0.0041

(-1.39%)

At close: April 11 at 4:00:01 PM EDT

0.3198

+0.03

+(9.90%)

After hours: April 11 at 6:41:41 PM EDT

Invivyd, Inc. (IVVD) Reports Q4 Loss, Tops Revenue Estimates

Invivyd, Inc. (IVVD) delivered earnings and revenue surprises of 40% and 2.75%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks 22 days ago

IVVD

SPRB
-1.39%
Spruce Biosciences (SPRB) Upgraded to Buy: Here's Why

Spruce Biosciences (SPRB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks 3 months ago

SPRB
-1.39%
Penny Stock Spruce Biosciences Winds Down Tildacerfont Studies For Rare Genetic Disorder

On Tuesday, Spruce Biosciences, Inc. (NASDAQ:SPRB) revealed topline results from its CAHmelia-204 study of tildacerfont in adult CAH and its CAHptain-205 study of tildacerfont in adult and pediatric CAH. Congenital adrenal hyperplasia (CAH) is a genetic disease that affects the adrenal glands and prevents the production of hormones like cortisol, aldosterone, and androgens. Also Read: Nano-Cap Spruce Biosciences Collaborates With HMNC Brain Health To Develop Treatment for Major Depressive Disord

Benzinga 3 months ago

SPRB
-1.39%
Spruce Biosciences Announces Topline Results from CAHmelia-204 in Adult CAH and CAHptain-205 in Adult and Pediatric CAH

SOUTH SAN FRANCISCO, Calif., December 10, 2024--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological and endocrine disorders with significant unmet medical need, today announced topline results from its CAHmelia-204 study of tildacerfont in adult CAH and its CAHptain-205 study of tildacerfont in adult and pediatric CAH.

Business Wire 3 months ago

SPRB
-1.39%
Spruce Biosciences Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag

Spruce Biosciences ( NASDAQ:SPRB ) Third Quarter 2024 Results Key Financial Results Revenue: US$602.0k (down 80% from...

Simply Wall St. 4 months ago

SPRB
-1.39%
Spruce Biosciences Reports Q3 2024 Earnings and Updates

Spruce Biosciences, Inc. ( (SPRB) ) has released its Q3 earnings. Here is a breakdown of the information Spruce Biosciences, Inc. presented to its investors. Spruce Biosciences, Inc. is a late-stage biopharmaceutical company focusing on developing and commercializing novel therapies for endocrine and neurological disorders, with a key focus on congenital adrenal hyperplasia (CAH). In their third-quarter 2024 earnings report, Spruce Biosciences highlighted upcoming data releases from significant

TipRanks 4 months ago

SPRB
-1.39%
Spruce Biosciences, Inc. (SPRB) Reports Q3 Loss, Lags Revenue Estimates

Spruce Biosciences (SPRB) delivered earnings and revenue surprises of 22.22% and 66.56%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks 4 months ago

SPRB
-1.39%
Spruce Biosciences Reports Third Quarter 2024 Financial Results and Provides Corporate Updates

SOUTH SAN FRANCISCO, Calif., November 11, 2024--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and neurological disorders with significant unmet medical need, today reported financial results for the third quarter ended September 30, 2024 and provided corporate updates.

Business Wire 4 months ago

SPRB
-1.39%
Spruce Biosciences to Participate in the Guggenheim Securities Healthcare Innovation Conference

SOUTH SAN FRANCISCO, Calif., October 28, 2024--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and neurological disorders with significant unmet medical need, today announced that Javier Szwarcberg, M.D., M.P.H., Chief Executive Officer, will present at the Guggenheim Securities Healthcare Innovation Conference on November 11, 2024, at 3:30 p.m. ET.

Business Wire 5 months ago

SPRB
-1.39%
Spruce Biosciences to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

SOUTH SAN FRANCISCO, Calif., September 03, 2024--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and neurological disorders with significant unmet medical need, today announced that Javier Szwarcberg, M.D., M.P.H., Chief Executive Officer, will present at the H.C. Wainwright 26th Annual Global Investment Conference on September 10, 2024, at 4:30 p.m. ET.

Business Wire 7 months ago

SPRB
-1.39%
Spruce Biosciences, Inc. (SPRB) Reports Q2 Loss, Tops Revenue Estimates

Spruce Biosciences (SPRB) delivered earnings and revenue surprises of 33.33% and 3.87%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks 7 months ago

SPRB
-1.39%
Spruce Biosciences Reports Second Quarter 2024 Financial Results and Provides Corporate Updates

SOUTH SAN FRANCISCO, Calif., August 12, 2024--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and neurological disorders with significant unmet medical need, today reported financial results for the second quarter ended June 30, 2024 and provided corporate updates.

Business Wire 7 months ago

SPRB
-1.39%
Pipeline Moves: Approval prospects for BioTissue’s diabetic foot ulcer drug up after Phase III completion

The Clinical Trials Arena team evaluates assets in cardiovascular, dermatology and oncology.

Clinical Trials Arena 9 months ago

GLDAF

REGN

SPRB
-1.39%
Spruce Biosciences Recognized as a Bay Area Best Place to Work

SOUTH SAN FRANCISCO, Calif., June 06, 2024--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and neurological disorders with significant unmet medical need, announced that the San Francisco Business Times and the Silicon Valley Business Journal have recognized the company as a Best Place to Work in 2024.

Business Wire 9 months ago

SPRB
-1.39%
Nano-Cap Spruce Biosciences Collaborates With HMNC Brain Health To Develop Treatment for Major Depressive Disorder

Spruce Biosciences Inc. (NASDAQ:SPRB) and HMNC Brain Health GmbH have collaborated to develop Spruce’s investigational product candidate, tildacerfont, and HMNC’s companion diagnostic, the proprietary Cortibon Genetic Selection Tool for major depressive disorder (MDD). Spruce Biosciences is a late-stage biopharmaceutical company developing its wholly-owned product candidate, tildacerfont, for classic congenital adrenal hyperplasia, polycystic ovary syndrome, and MDD. “We believe that Cortibon ha

Benzinga 10 months ago

SPRB
-1.39%
Spruce Biosciences and HMNC Brain Health Announce Strategic Collaboration to Develop Treatment for Major Depressive Disorder (MDD)

SOUTH SAN FRANCISCO, Calif. & MUNICH, June 04, 2024--Spruce Biosciences, Inc. (Nasdaq: SPRB) ("Spruce"), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and neurological disorders with significant unmet medical need, and HMNC Brain Health GmbH ("HMNC"), a global precision psychiatry biopharma company, announced today a strategic collaboration to develop Spruce’s investigational product candidate, tildacerfont, a second-generation CRF

Business Wire 10 months ago

SPRB
-1.39%
Spruce Biosciences Presented Phase 2 POWER Study Results of Tildacerfont for the Treatment of Polycystic Ovary Syndrome at ENDO 2024

SOUTH SAN FRANCISCO, Calif., June 03, 2024--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine disorders with significant unmet medical need, presented results from its Phase 2 POWER study of tildacerfont, a second-generation CRF1 receptor antagonist, for the treatment of polycystic ovary syndrome (PCOS) at the 2024 Annual Meeting of the Endocrine Society (ENDO 2024).

Business Wire 10 months ago

SPRB
-1.39%
Spruce Biosciences to Participate in the Jefferies Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif., May 23, 2024--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that Javier Szwarcberg, M.D., M.P.H., Chief Executive Officer, will present at the Jefferies Global Healthcare Conference on June 5, 2024, at 5:00 p.m. ET.

Business Wire 10 months ago

SPRB
-1.39%
Spruce Biosciences Announces Poster Presentations at the 2024 Annual Meeting of the Endocrine Society

SOUTH SAN FRANCISCO, Calif., May 22, 2024--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that three submitted abstracts were accepted for the 106th Annual Meeting of the Endocrine Society (ENDO 2024) taking place June 1-4, 2024, in Boston.

Business Wire 10 months ago

SPRB
-1.39%
Spruce Biosciences, Inc. (SPRB) Reports Q1 Loss, Tops Revenue Estimates

Spruce Biosciences (SPRB) delivered earnings and revenue surprises of 12.50% and 79.55%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks 10 months ago

SPRB
-1.39%

Performance Overview

Return	SPRB	S&P 500 (^GSPC)
YTD	-30.71%	-8.81%
1-Year	-61.91%	+3.16%
3-Year	-84.68%	+21.55%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Spruce Biosciences, Inc. (SPRB)

Invivyd, Inc. (IVVD) Reports Q4 Loss, Tops Revenue Estimates

Spruce Biosciences (SPRB) Upgraded to Buy: Here's Why

Penny Stock Spruce Biosciences Winds Down Tildacerfont Studies For Rare Genetic Disorder

Spruce Biosciences Announces Topline Results from CAHmelia-204 in Adult CAH and CAHptain-205 in Adult and Pediatric CAH

Spruce Biosciences Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag

Spruce Biosciences Reports Q3 2024 Earnings and Updates

Spruce Biosciences, Inc. (SPRB) Reports Q3 Loss, Lags Revenue Estimates

Spruce Biosciences Reports Third Quarter 2024 Financial Results and Provides Corporate Updates

Spruce Biosciences to Participate in the Guggenheim Securities Healthcare Innovation Conference

Spruce Biosciences to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

Spruce Biosciences, Inc. (SPRB) Reports Q2 Loss, Tops Revenue Estimates

Spruce Biosciences Reports Second Quarter 2024 Financial Results and Provides Corporate Updates

Pipeline Moves: Approval prospects for BioTissue’s diabetic foot ulcer drug up after Phase III completion

Spruce Biosciences Recognized as a Bay Area Best Place to Work

Nano-Cap Spruce Biosciences Collaborates With HMNC Brain Health To Develop Treatment for Major Depressive Disorder

Spruce Biosciences and HMNC Brain Health Announce Strategic Collaboration to Develop Treatment for Major Depressive Disorder (MDD)

Spruce Biosciences Presented Phase 2 POWER Study Results of Tildacerfont for the Treatment of Polycystic Ovary Syndrome at ENDO 2024

Spruce Biosciences to Participate in the Jefferies Global Healthcare Conference

Spruce Biosciences Announces Poster Presentations at the 2024 Annual Meeting of the Endocrine Society

Spruce Biosciences, Inc. (SPRB) Reports Q1 Loss, Tops Revenue Estimates

Performance Overview